Fine Needle Aspiration of a Neck Mass: Lymphoid-Rich Smear with a Diagnostic Dilemma
A 58-year-old woman presents with a 3-cm left level II neck mass, slowly enlarging over 6 months, with no fever or weight loss. Ultrasound shows a solid, hypoechoic mass with internal vascularity. FNA yields cellular smears composed predominantly of small lymphocytes with scattered tingible-body macrophages and a few larger cells with irregular nuclei. Flow cytometry on the aspirate shows a polyclonal B-cell population and a normal T-cell subset distribution. The cytopathologist must decide whether to sign out as 'reactive lymphoid hyperplasia' or to pursue further workup.
1. What are the differential diagnostic considerations, and why is a polyclonal flow result not fully reassuring?
Read the worked answer
The differential for a lymphoid-rich neck mass in this age group includes reactive lymphadenopathy, low-grade B-cell lymphoma (including marginal zone lymphoma and follicular lymphoma), Hodgkin lymphoma, metastatic carcinoma with lymphoid stroma, and, depending on location, a salivary gland or branchial cleft lesion. Flow cytometry showing polyclonal B cells and normal T-cell subsets argues against a clonal B-cell lymphoma but does not exclude it: small samples can miss a clonal population, and some lymphomas (e.g., Hodgkin lymphoma, T-cell lymphomas, and certain low-grade B-cell lymphomas with scant neoplastic cells) may not demonstrate a detectable clone by flow. The cytomorphology-small lymphocytes with tingible-body macrophages-is compatible with reactive hyperplasia, but the persistent, enlarging, vascular solid mass in a 58-year-old is clinically concerning.
2. What is the appropriate next step, and how should the report be worded?
Read the worked answer
The appropriate next step is to avoid a definitive benign diagnosis on cytology alone. Options include: (1) recommending excisional biopsy of the node for architectural and immunohistochemical evaluation, which is the gold standard for diagnosing lymphoma; (2) if a core needle biopsy is feasible, obtaining one for histology and ancillary studies (immunohistochemistry, possibly molecular clonality studies); and (3) correlating with clinical findings and imaging. The report should be descriptive and cautious-e.g., 'Atypical lymphoid proliferation; flow cytometry shows a polyclonal B-cell population, but sampling limitations preclude exclusion of lymphoma; excisional biopsy is recommended.' This communicates uncertainty, avoids false reassurance, and directs the clinician to the definitive diagnostic procedure.